Literature DB >> 9135411

Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific.

B Laliotou1, J Liversidge, J V Forrester, A D Dick.   

Abstract

AIMS: Administration of unfractionated retinal antigen(s) (retinal extract, RE) suppresses RE induced experimental autoimmune uveoretinitis (EAU) and offers a potential therapeutic alternative to non-specific immunosuppressive therapies for posterior uveitis and autoimmune diseases. S-Ag and interphotoreceptor retinoid binding protein (IRBP) are two major autoantigens within soluble RE. It was aimed to assess, firstly, as has previously been shown with S-Ag, if IRBP can induce intranasal tolerance and, secondly, the contribution of both these major autoantigens to tolerance induction by whole RE.
METHODS: Animals were tolerised by intranasal administration with S-Ag or IRBP, either alone or in combination, or RE before immunisation with either IRBP or RE. Control animals were administered nasally either PBS or MBP. Daily clinical responses were recorded biomicroscopically and histological grades were obtained using a semiquantitative scoring system. Weekly serum antibody levels to retinal antigens were measured by ELISA and delayed hypersensitivity responses (DTH) were assessed by skin reactivity to intradermal inoculation with retinal or non-specific antigens.
RESULTS: Microgram doses of IRBP successfully suppressed both clinically and histologically IRBP induced EAU. This suppression was accompanied by reduced antigen specific DTH reactivity but maintained T cell dependent (IgG2a) antibody responses. Furthermore, combined S-Ag and IRBP administration afforded equal suppression of RE induced EAU when compared with RE therapy alone. Suppression of RE induced EAU was not achieved with administration of a non-retinal specific autoantigen, MBP. Although individually, both S-Ag and IRBP suppressed RE induced EAU, whole RE was unable to protect against IRBP induced disease.
CONCLUSIONS: Intranasal administration of IRBP suppressed IRBP induced EAU in the Lewis rat. S-Ag and IRBP are the major contributors to the tolerogenicity within RE, despite the known uveogenicity of other retinal antigens within RE and induction of tolerance was retinal antigen specific. Furthermore, suppression induced by single antigen administration is antigen specific although concomitant bystander suppression may also play a role. RE was unable to protect against IRBP induced disease despite tolerogenic levels of antigen within RE. Although this may be due in part to a dose effect of either tolerising or immunising antigen, further investigation into the possible antigen dominance of IRBP or mucosal processing of combinations of antigens is necessary so that the full efficacy of mucosal tolerance therapy can be assessed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9135411      PMCID: PMC1722010          DOI: 10.1136/bjo.81.1.61

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  24 in total

1.  Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity.

Authors:  B Metzler; D C Wraith
Journal:  Int Immunol       Date:  1993-09       Impact factor: 4.823

2.  Regulation of IgE responses to inhaled antigen in mice by antigen-specific gamma delta T cells.

Authors:  C McMenamin; C Pimm; M McKersey; P G Holt
Journal:  Science       Date:  1994-09-23       Impact factor: 47.728

Review 3.  Immunomodulation of experimental autoimmune uveoretinitis: a model of tolerance induction with retinal antigens.

Authors:  A D Dick; Y F Cheng; J Liversidge; J V Forrester
Journal:  Eye (Lond)       Date:  1994       Impact factor: 3.775

4.  Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

Authors:  H L Weiner; G A Mackin; M Matsui; E J Orav; S J Khoury; D M Dawson; D A Hafler
Journal:  Science       Date:  1993-02-26       Impact factor: 47.728

5.  Oral tolerance in experimental autoimmune uveoretinitis. Distinct mechanisms of resistance are induced by low dose vs high dose feeding protocols.

Authors:  D S Gregerson; W F Obritsch; L A Donoso
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

6.  In vivo tolerization of Th1 lymphocytes following a single feeding with ovalbumin: anergy in the absence of suppression.

Authors:  D Melamed; A Friedman
Journal:  Eur J Immunol       Date:  1994-09       Impact factor: 5.532

7.  Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin.

Authors:  D Melamed; A Friedman
Journal:  Eur J Immunol       Date:  1993-04       Impact factor: 5.532

8.  Inhibition of experimental autoimmune uveoretinitis by oral administration of S-antigen and synthetic peptides.

Authors:  T R Vrabec; D S Gregerson; H S Dua; L A Donoso
Journal:  Autoimmunity       Date:  1992       Impact factor: 2.815

9.  Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis.

Authors:  Y Chen; V K Kuchroo; J Inobe; D A Hafler; H L Weiner
Journal:  Science       Date:  1994-08-26       Impact factor: 47.728

10.  Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain.

Authors:  S J Khoury; W W Hancock; H L Weiner
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  3 in total

1.  Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis.

Authors:  Cathryn Broderick; Robert M Hoek; John V Forrester; Janet Liversidge; Jonathon D Sedgwick; Andrew D Dick
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 2.  Ocular allergy guidelines: a practical treatment algorithm.

Authors:  Leonard Bielory
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration.

Authors:  Jolanda H M van Bilsen; Josée P A Wagenaar-Hilbers; Maarten J F van der Cammen; Mariska E A van Dijk; Willem van Eden; Marca H M Wauben
Journal:  Arthritis Res       Date:  2002-05-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.